Playing Offense in Part D: Three Aggressive Medicare Strategies Demand Pharma Attention
This article was originally published in RPM Report
Humana thrilled CMS-and shocked its competitors-by offering stand-alone drug insurance plans under Medicare for less than $10 per month. Pharmaceutical manufacturers should applaud. Not all Part D strategies are equal for pharma companies. Manufacturers should compare Humana's approach to other aggressive bids by UnitedHealth and WellCare.
You may also be interested in...
Part D has reached a significant milestone: for the first time, a majority of beneficiaries in the outpatient drug program are also enrolled in fully integrated Medicare Advantage plans. That opens up opportunities to learn more about value-based designs and longer-term outcomes.
In the run up to its launch in 2006, Part D was politically controversial and there was considerable skepticism about the logistical challenges for implementation. That experience is reassuring for implementers of the Affordable Care Act – but advocates should be wary of relying too much on parallels to Part D.
An inspector General report takes the first public look at rebating under Medicare Par D.For Henry Waxman the message is that private negotiation isn't working to capture deep enough discounts. But the more important message for sponsors is that the report shows CMS remains firmly committed to the private sector drug insurance model.